R-Lipoïc Acide Sodium Salt 300mg
Food supplement declared in France, declaration No 2020-5-1051, decision dated 20 May 2020
R-Lipoïc Acide Sodium Salt 300mg, from ORONALYS SARL, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: R-alpha lipoate de sodium. None of the rules we check flags an issue with its declared composition.
- Brand
- not provided
- Food business operator placing the product on the market
- ORONALYS SARL
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Intended populations
- Men, Women
- Not recommended (according to the manufacturer)
- Breastfeeding women, Children (under 12), Pregnant women
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxidant
Declaration 168968, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Other active ingredients
| Name | Per day |
|---|---|
| R-alpha lipoate de sodium | not declared |
Additives
E460, Hydroxypropyl Méthyl Cellulose
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ce complément alimentaire doit être utilisé dans le cadre d’un régime alimentaire varié et équilibré. Il est important d’avoir un mode de vie sain. Ne pas dépasser la dose journalière recommandée. Conserver dans un endroit frais et sec. Ne convient pas aux enfants, aux personnes diabétiques, aux femmes enceintes et en période d’allaitement. Tenir hors de portée des enfants.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- R-alpha lipoate de sodium
Read the warning, when it applies and the studies cited
DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).
Sources cited by Health Canada (3)
- Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
- Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
- Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article
Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).
Sources cited by Health Canada (4)
- Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
- Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
- Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
- Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- R-Lipoïc Acide Sodium Salt 300mg BIOFILUX NUTRITION SARL, declared in 2024 : different composition: 3 ingredient(s) added, 3 missing
- R-Lipoïc Acide Sodium Salt 300mg BIOFILUX NUTRITION SARL, declared in 2024 : different composition: 3 ingredient(s) added, 3 missing
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “R-Lipoïc Acide Sodium Salt 300mg: composition and regulation”, https://compoatlas.com/en/supplements/products/168968-r-lipoic-acide-sodium-salt-300mg, updated 15 November 2026.